



---

# Drug Information Update

December 2022



## TABLE OF CONTENTS

---

TABLE OF CONTENTS.....	1
NEWLY AVAILABLE GENERICS .....	2
NEW DRUG ENTITIES/STRENGTHS/COMBINATIONS .....	3
NEW INDICATIONS (EXISTING DRUGS).....	6
RECALLS .....	11
CURRENT DRUG SHORTAGES .....	15



## NEWLY AVAILABLE GENERICS

Generic Name/ Dosage Form	Brand Name	Manufacturer	Indication
Tafluprost preservative-free 0.0015% dropperette	Zioptan	Akorn Inc.	For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Methylphenidate ER 45 mg, 63 mg oral tablet	Relexxii	Osmotica Pharma US	For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older
Bendamustine 25 mg, 100 mg IV vial	Treanda	Cephalon	An alkylating drug indicated for treatment of patients with: <ul style="list-style-type: none"><li>• Chronic lymphocytic leukemia (CLL)</li><li>• Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen</li></ul>

## NEW DRUG ENTITIES/STRENGTHS/COMBINATIONS

Drug Name	Generic Name	Description	Comments
Tzield 1 mg/mL intravenous solution	teplizumab-mzww	CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.	New Entity
Ermeza 30 mcg/mL oral solution	levothyroxine sodium	New oral solution formulation of levothyroxine.	New Formulation
bortezomib 1 mg/mL intravenous solution	bortezomib	New pre-mixed formulation of bortezomib at the 1 mg/mL strength. Previously only available as 1 mg vials for reconstitution.	New Formulation
Elucirem 0.5 mmol/mL intravenous solution	gadopiclenol	Diagnostic agent indicated in patients age 2 years and older for use with MRI imaging to detect lesions with abnormal vascularity.	New Entity
Elucirem 3.75 mmol/7.5 mL, 5 mmol/10 mL, 7.5 mmol/15 mL intravenous syringe	gadopiclenol	Diagnostic agent indicated in patients age 2 years and older for use with MRI imaging to detect lesions with abnormal vascularity.	New Entity
Hemgenix $1 \times 10^{13}$ gene copies/mL intravenous suspension	etranacogene dezaparvovec-drlb	Novel gene therapy that acts as a potential cure for hemophilia B. It is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes. Cost will be \$3.5 million.	New Entity
Rezlidhia 150 mg capsule	olutasidenib	Novel, non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).	New Entity
Rebyota 150 mL enema	fecal microbiota, live-jslm	For the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age	New Entity

Drug Name	Generic Name	Description	Comments
		and older, following antibiotic treatment for recurrent CDI. Cost is \$9,000 per single-dose treatment.	
Tascenso ODT 0.5 mg disintegrating tablet	fingolimod lauryl sulfate	New strength. Previously only available in 0.25 mg tablets. Sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.	New Strength
Krazati 200 mg tablet	adagrasib	Inhibitor of the RAS GTPase family indicated for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This was approved based upon objective response rate (ORR) and duration of response (DOR). Continued approval will be contingent upon a clinical benefit in confirmatory trials.	New Entity
Stimufend 6 mg/0.6 mL subcutaneous syringe	pegfilgrastim-fpgk	New biosimilar for Neulasta indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Lacks the Hematopoietic Subsyndrome of Acute Radiation Syndrome indication.	Biosimilar for Neulasta
Daxxify 100 unit intramuscular solution	daxibotulinumtoxina-lanm	New neurotoxin long-acting agent that will compete with Botox for cosmetic use. It is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines	New Entity

Drug Name	Generic Name	Description	Comments
		associated with corrugator and/or procerus muscle activity in adult patients. Also being studied for cervical dystonia, upper limb spasticity, and plantar fasciitis.	

## NEW INDICATIONS (EXISTING DRUGS)

†**Bolded** items reflect newly approved indication; ~~strike through~~ of removed indication/age limit/etc.

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
Brexafemme	ibrexafungerp citrate 150 mg oral tablet	Scynexis	Triterpenoid antifungal indicated in adult and post-menarchal pediatric females for: <ul style="list-style-type: none"> <li>• Treatment of vulvovaginal candidiasis (VVC)</li> <li>• <b>Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)</b></li> </ul>
Udenyca	pegfilgrastim-cbqv 6 mg/0.6 mL syringe	Coherus Biosciences	Leukocyte growth factor indicated to: <ul style="list-style-type: none"> <li>• Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia</li> <li>• <b>Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)</b></li> </ul>
Tecentriq	atezolizumab 840 mg/14 mL, 1200 mg/20 mL IV vial	Genentech	Programmed death-ligand 1 (PD-L1) blocking antibody indicated: <p><b><u>Urothelial Carcinoma</u></b></p> <ul style="list-style-type: none"> <li>• <del>For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:</del></li> <li>• <del>are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), as determined by an FDA-approved test, or</del></li> <li>• <del>are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status</del></li> </ul> <p><b><u>Non-Small Cell Lung Cancer (NSCLC)</u></b></p> <ul style="list-style-type: none"> <li>• As adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors</li> </ul>

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			<p>have PD-L1 expression on <math>\geq 1\%</math> of tumor cells, as determined by an FDA-approved test</p> <ul style="list-style-type: none"> <li>For the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained <math>\geq 50\%</math> of tumor cells [TC <math>\geq 50\%</math>] or PD-L1 stained tumor-infiltrating immune cells [IC] covering <math>\geq 10\%</math> of the tumor area [IC <math>\geq 10\%</math> ]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations</li> <li>In combination with bevacizumab, paclitaxel, and carboplatin, for the firstline treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.</li> <li>In combination with paclitaxel protein-bound and carboplatin for the firstline treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy</li> </ul> <p><b><u>Small Cell Lung Cancer (SCLC)</u></b></p> <ul style="list-style-type: none"> <li>In combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)</li> </ul> <p><b><u>Hepatocellular Carcinoma (HCC)</u></b></p> <ul style="list-style-type: none"> <li>In combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy</li> </ul> <p><b><u>Melanoma</u></b></p> <ul style="list-style-type: none"> <li>In combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma</li> </ul>



Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			<p><b><u>Alveolar Soft Part Sarcoma (ASPS)</u></b></p> <ul style="list-style-type: none"> <li>For the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS</li> </ul>
Zejula	niraparib 100 mg oral capsule	GlaxoSmithKline	<ul style="list-style-type: none"> <li>For the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy</li> <li>For the maintenance treatment of adult patients with <b>deleterious or suspected deleterious germline BRCA-mutated (gBRCAmut)</b> recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy</li> </ul>
Velcade	bortezomib 1 mg, 2.5 mg IV vials	Takeda	<ul style="list-style-type: none"> <li>For the treatment of adult patients with multiple myeloma</li> <li>For the treatment of adult patients with mantle cell lymphoma <del>who have received at least 1 prior therapy</del></li> </ul>
Xeloda	capecitabine 150 mg, 500 mg oral tablet	Genentech	<p>Nucleoside metabolic inhibitor indicated for:</p> <p><del>Adjuvant Colon Cancer</del>  <del>Patients with Dukes' C colon cancer</del>  <del>Metastatic Colorectal Cancer</del>  <del>First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred</del>  <del>Metastatic Breast Cancer</del>  <del>In combination with docetaxel after failure of prior anthracycline-containing therapy</del>  <del>As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen</del></p> <p><b>Colorectal Cancer</b></p> <ul style="list-style-type: none"> <li>Adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen</li> <li>Perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy</li> </ul>

Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			<ul style="list-style-type: none"> <li>• Treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen</li> </ul> <p><b>Breast Cancer</b></p> <ul style="list-style-type: none"> <li>• Treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated</li> <li>• Treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy</li> </ul> <p><b>Gastric, Esophageal, or Gastroesophageal Junction Cancer</b></p> <ul style="list-style-type: none"> <li>• Treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen</li> <li>• Treatment of adults with HER2- overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen</li> </ul> <p><b>Pancreatic Cancer</b></p> <ul style="list-style-type: none"> <li>• Adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen</li> </ul> <p><b>*All indications have updated language.</b></p>
Veklury	remdesivir 100 mg IV vial	Gilead Sciences	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) <del>with positive results of direct SARS-CoV-2 viral testing, who are:</del></p>



Brand Name	Generic Name/ Dosage Form	Manufacturer	Newly Approved Indication†
			<ul style="list-style-type: none"><li>• Hospitalized, or</li><li>• Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death</li></ul>

## RECALLS

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx only, Manufactured and Distributed by: Exela Pharma Sciences, LLC Lenoir, NC 28645. Carton NDC 51754-5001-5, vial NDC 51754-5001-1.	Class I	Drugs	Lots: P0001178 Exp. 05/2023; P0001298, P0001301, P0001313, P0001314, P0001317 Exp. 08/2023; P0001330, P0001464 Exp. 09/2023; P0001442 Exp. 11/2023; P0001467, P0001472, P0001486, P0001532 Exp. 12/2023.	Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.	Exela Pharma Sciences LLC
8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx Only, Mfd for: Civica, Inc. Lehi, Utah 84043, Mfd by: Exela Pharma Sciences, LLC, Lenoir, NC 28645, Carton NDC 72572-740-20, vial NDC 72572-740-1.	Class I	Drugs	Lot: P0001490 Exp. 12/2023	Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.	Exela Pharma Sciences LLC
Iohexol (300 mg Iodine/mL), 2.4 g Iodine/8 ml, Total Volume 8 ml in 10 ml syringe, 5-count syringes packaged in a bag labeled as Omnipaque (iohexol) 300 mg I/mL, 2.4g Iodine/8 mL in a 10 mL syringe, Compounded with GE Healthcare product, Each mL contains (647 mg) of iohexol as 300 mg of organically bound iodine, 1.21 mg tromethamine, and 0.1 mg edetate calcium disodium, For Injection or oral use; Rx Only,	Class I	Drugs	Lot: IOHE2.420221128, Exp. 12/7/2022	Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL	BayCare Integrated Service Center, LLC /dba BayCare Central Pharmacy

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
BayCare Central Pharmacy, 7802 Telecom Parkway, Temple Terrace, FL 33637.					
Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours, (1.6 mg/hr), 30 patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186; By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC 68968-5553-3.	Class II	Drugs	Lot: 91316 Exp. 02/2023	Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.	Noven Pharmaceuticals Inc
Desmopressin Acetate Tablets 0.2mg, 100-count bottles, RX Only, Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816, NDC 23155-490-01	Class II	Drugs	Lot #: 220440A, Exp. Date 05/2024	Subpotent Drug	Heritage Pharmaceuticals Inc
0.9% Sodium Chloride Injection USP 1000 mL Single-dose container Rx only NDC 0264-5802-00 B. Braun Medical Inc. Bethlehem, PA 18018-3524 USA 1-800-227-2862	Class II	Drugs	Lot: 0061832446 Exp. 31 Oct 2024	Lack of sterility assurance: Bags have the potential to leak.	B. Braun Medical, Inc.
0.9% Sodium Chloride Injection, USP, Each 100 mL contains: SODIUM CHLORIDE, USP - 900 mg, WATER FOR INJECTION, USP - qs, 1000mL Bag, 12 PK, Rx Only, Fresenius Medical Care North America, Waltham, MA 02451, NDC 49230-300-10	Class II	Drugs	Lot # 22HU05062, 22HU06059, 22HU05035, EXP 06/30/2023; 22JU05001, EXP 07/31/2023	Lack of Assurance of Sterility: Leakage of 0.9% Sodium Chloride for Injection, 1L, 12pk Saline Solution.	Fresenius Medical Care Holdings, Inc.
Desmopressin Acetate Tablet, 0.2 mg, 100-count box, Rx only, Source NDC: 23155-0490-01; MFG: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816; Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC #: 70518-3493-00.	Class II	Drugs	Lot # B1817019-082222, Exp. 02/24/2023; B1819127-082322, Exp. 02/26/2023	Subpotent Drug: repackaged product was recalled by the manufacturer for subpotency.	RemedyRepack Inc.
FentaNYL Citrate 2.5 mg/50 mL (50mcg/ml) Injection Solution, Preservative Free, Single	Class II	Drugs	Lots: 100122060007 Exp. 12/17/2022;	Underfilled units.	OurPharma LLC

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
Use 50 ml Cassette, Rx Only, Repackaged by OurPharma, LLC. 2512 S. City Lake Rd. Fayetteville, AR 72701, 1-833-290-2654, NDC 73013-001-01			100122060008 Exp. 12/18/2022; 100122070002 Exp. 01/09/2023.		
Neuroquell Plus, Advanced Formula, A Homeopathic Drug, Calendula Oil packaged in 0.22 Fl. oz. (6.6 mL) bottles, Mfg. for/Dist. By Claire Ellen Topicals, P.O. Box 901 Westborough, MA 01581, USA, NDC# 66233712-01.	Class II	Drugs	Lot Code B-02	cGMP Deviations	Atlantic Management Resources Ltd.
Neuroquell, A Homeopathic Drug, Calendula Oil, packaged in 1/8 Fl. oz. (3.5 g) bottles, Mfg. for/Dist. By Claire Ellen Topicals, P.O. Box 901 Westborough, MA 01581, USA, NDC# 66233712-01.	Class II	Drugs	Lot Code B-02	cGMP Deviations	Atlantic Management Resources Ltd.
ProSirona, A Homeopathic Formula, Calendula Oil packaged in 1/8 Fl. oz. (3.5 g) bottles, Dist. by: Endometriosis Assoc. Inc. (International), Mfg. by Claire Ellen Topicals, P.O. Box 901 Westborough, MA 01581, USA, NDC# 66233-712-01.	Class II	Drugs	Lot Code B-02	cGMP Deviations	Atlantic Management Resources Ltd.
Menastil, A Homeopathic Formula, Calendula Oil packaged in 1/8 Fl. oz. (3.5 g) bottles, Mfg. for/Dist. By Claire Ellen Topicals, P.O. Box 901 Westborough, MA 01581, USA, NDC# 66233-711-01.	Class II	Drugs	Lot Code A-01	cGMP Deviations	Atlantic Management Resources Ltd.
Oxcarbazepine Tablets 600mg, packaged in a) 100- count bottles (NDC 62756-185-88), b) 500-count bottles (NDC 62756-185-13), c) 1000-count bottles (NDC 62756-185-18),	Class II	Drugs	a) Lot HAC1474A, Expires 03/2023 b) Lot HAC1503A, Expires 03/2023 c) Lot	Presence of foreign substance	SUN PHARMACEUTICAL

Product Description	Classification	Product Type	Code Info	Reason for recall	Recalling Firm
Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India.			HAC1474B, Expires 03/2023		INDUSTRIES INC
Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01	Class II	Drugs	Lots: 01422002A1, Expiry: 12/2023; 01421078A3, Expiry: 09/2023	Failed Impurities/Degradation Specifications	Aurolife Pharma, LLC
Sodium Sulfacetamide 10% Sulfur 4% Cleansing Pads, Net weight 3.7g (60 cleansing pads Net weight 3.7 g each per carton,) Rx Only, Manufactured For: Acella Pharmaceuticals, LLC Alpharetta, GA 300025, NDC 42192-113-60	Class III	Drugs	Lot#: 21084, 21085, Exp 06/30/2023	Subpotent drug: Out of specification for assay at the end-of-shelf-life 24-month period.	Acella Pharmaceuticals, LLC
Allergy Relief D, Fexofenadine HCL 60mg/Antihistamine, Pseudoephedrine HCL 120mg/Nasal Decongestant, Extended-Release Tablets USP, packaged as (a) 20 count carton NDC 49032-273-20; (b) 30 count carton, NDC49032-273-30; Distributed by: Walmart Inc., Bentonville, AR 72716, Product of India	Class III	Drugs	Lot# (a) AC2203133B, EXP 01/2024; (b) AC2203133A, EXP 01/2024.	Failed dissolution specifications	Dr. Reddy's Laboratories, Inc.

\*Please refer to FDA website for further information at: <http://www.fda.gov/Safety/Recalls>

## CURRENT DRUG SHORTAGES

---

Below is the list of drugs listed by the FDA as currently in shortage. Please refer to the FDA website for more information at: <https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>

### Generic Name or Active Ingredient

Albuterol Sulfate Inhalational Solution  
Alprostadil (Muse) Suppository  
Amifostine Injection  
Amino Acids  
Amoxapine Tablets  
Amoxicillin Oral Powder for Suspension  
Amphetamine; Dextroamphetamine Tablets  
Atropine Sulfate Injection  
Azacitidine for Injection  
Azithromycin (Azasite) Ophthalmic Solution 1%  
Bacteriostatic 0.9% Sodium Chloride Injection  
Bacteriostatic Water for Injection  
Belatacept (Nulojix) Lyophilized Powder for Injection  
Belladonna and Opium Suppositories  
Bumetanide Injection  
Bupivacaine Hydrochloride and Epinephrine Injection  
Bupivacaine Hydrochloride Injection  
Calcium Gluconate Injection  
Cefixime Oral Capsules  
Cefotaxime Sodium Injection  
Cefotetan Disodium Injection  
Chloroprocaine Hydrochloride Injection  
Chlorothiazide Oral Suspension  
Collagenase Ointment  
Conivaptan Hydrochloride (Vaprisol) in 5% Dextrose Plastic Container  
Conjugated Estrogens/Bazedoxifene (DUAVEE) Tablet, Film Coated  
Cyclopentolate Ophthalmic Solution  
Cytarabine Injection  
Dacarbazine Injection  
Desmopressin Acetate Nasal Spray  
Dexamethasone Sodium Phosphate Injection  
Dexmedetomidine Injection  
Dextrose 10% Injection  
Dextrose 25% Injection  
Dextrose 5% Injection  
Dextrose 50% Injection  
Diazepam Rectal Gel  
Diflunisal Tablets





Difluprednate Ophthalmic Emulsion  
Digoxin Injection  
Diltiazem Hydrochloride Injection  
Disopyramide Phosphate (Norpace) Capsules  
Dobutamine Hydrochloride Injection  
Dopamine Hydrochloride Injection  
Dulaglutide (Trulicity) Injection  
Echothiophate Iodide (Phospholine Iodide) Ophthalmic Solution  
Edetate Calcium Disodium Injection  
Enalaprilat Injection  
Epinephrine Injection, 0.1 mg/mL  
Erythromycin Ophthalmic Ointment  
Etomidate Injection  
Fentanyl Citrate (Sublimaze) Injection  
Floxuridine for Injection  
Fludarabine Phosphate Injection  
Flurazepam Hydrochloride Capsules  
Furosemide Injection  
Gentamicin Sulfate Injection  
Guanfacine Hydrochloride Tablets  
Heparin Sodium and Sodium Chloride 0.9% Injection  
Hydromorphone Hydrochloride Injection  
Hydroxypropyl (Lacrisert) Cellulose Ophthalmic Insert  
Ibutilide Fumarate Injection  
Indigotindisulfonate Sodium Injection  
Iomeprol injection  
Isoniazid Injection  
IV Fat Emulsion  
Ketamine Injection  
Ketorolac Tromethamine Injection  
Leucovorin Calcium Lyophilized Powder for Injection  
Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags  
Lidocaine Hydrochloride (Xylocaine) Injection  
Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine  
Lithium Oral Solution  
Lorazepam Injection  
Mannitol Injection  
Mepivacaine Hydrochloride Injection  
Methyldopa Tablets  
Methylprednisolone Acetate Injection  
Metronidazole Injection  
Midazolam Injection  
Morphine Sulfate Injection  
Multi-Vitamin Infusion (Adult and Pediatric)  
Neomycin Sulfate Tablets  
Nizatidine Capsules



Oxybutynin Chloride Syrup  
Oxytocin Injection  
Paclitaxel Injection (protein-bound particles)  
Pantoprazole Sodium for Injection  
Parathyroid Hormone (Natpara) Injection  
Pentostatin Injection  
Physostigmine Salicylate Injection  
Potassium Acetate Injection  
Potassium Chloride Concentrate Injection  
Remifentanil Injection  
Rifampin Capsules  
Rifampin Injection  
Rifapentine Tablets  
Ropivacaine Hydrochloride Injection  
Semaglutide (Ozempic) Injection  
Semaglutide (WEGOVY®) Injection  
Sinalide (Kinevac) Lyophilized Powder for Injection  
Sodium Acetate Injection  
Sodium Bicarbonate Injection  
Sodium Chloride 0.9% Injection Bags  
Sodium Chloride 14.6% Injection  
Sodium Chloride 23.4% Injection  
Sodium Chloride Injection USP, 0.9% Vials and Syringes  
Sodium Phosphates Injection  
Sterile Water for Injection  
Streptozocin (Zanosar) Sterile Powder  
Sufentanil Citrate Injection  
Sulfasalazine Tablets  
Technetium TC-99M Mebrofenin Injection  
Technetium TC-99m Sodium Pertechnetate Generator  
Technetium Tc99m Succimer Injection (DMSA)  
Teprotumumab-trbw  
Tirzepatide Injection  
Triamcinolone Acetonide Injectable Suspension  
Triamcinolone Hexacetonide Injectable suspension  
Trimethobenzamide Hydrochloride Capsules  
Valproate Sodium Injection  
Vecuronium Bromide for Injection  
Verteporfin (Visudyne) Injection